Covidien Hernia Mesh Verdict to Be Reduced: Judge Calls $88 Million Award a 'Product of Passion'

The $88 million Covidien hernia mesh verdict is going to be reduced: on Tuesday, November 10, 2026, U.S. District Judge Patti B. Saris told the parties in Patterson v. Covidien that the jury's award was shocking, excessive and appeared to be "the product of passion," and that she will cut it. No reduced number has been reported yet, but the ruling means Larry and Tammy Patterson of Etowah County, Alabama, will soon have to choose between accepting a lower award and retrying damages, and it removes the only nine-figure data point from the Medtronic hernia mesh litigation just two months before the second bellwether trial.

The decision lands in the middle of Covidien's post-trial challenge to the first federal bellwether in MDL No. 3029, In re Covidien Hernia Mesh Products Liability Litigation (No. II). Judge Saris had signaled in August that she was likely to trim the award. What changed on November 10 is that the signal became a ruling of intent, delivered in language strong enough to raise a second question the reports so far have not addressed: whether a verdict driven by passion can be fixed by remittitur alone, or whether Covidien will press for a full retrial.

Did the judge reduce the $88 million Covidien hernia mesh verdict?

Yes, in principle, though not yet in dollars. Judge Saris said on November 10, 2026 that she will reduce the $88 million award, according to contemporaneous reports from Law360 and Reuters. She described the award as "shocking and excessive" and said it appeared to be "the product of passion." The reports available on the day of the ruling do not state a reduced figure, and none should be assumed.

That gap matters, and it is the first thing practitioners should note. A judge's announcement that a verdict will be remitted is not the same as an order fixing the remitted amount, and it is not a final judgment. Until a written order sets the number and the plaintiffs respond, the Covidien hernia mesh verdict reduced on November 10 is reduced only in direction, not in amount.

What is known is the starting point. The jury in Boston returned its verdict on August 4, 2026, after a three-week trial that opened on July 13, 2026. It awarded:

Component	Jury finding (Aug. 4, 2026)	Status after Nov. 10, 2026
Failure to Warn (Symbotex)	Liability found for plaintiffs	Liability ruling not reported as disturbed
Fraud / intentional or reckless misrepresentation	Rejected	Unchanged
Compensatory damages, Larry Patterson	$77,000,000	To be reduced; amount not yet reported
Loss of consortium, Tammy Patterson	$11,000,000	Reduction scope not yet reported
Punitive Damages	None awarded	Unchanged
Total	$88,000,000	Pending written order

Every dollar of the $88 million was compensatory. That structural fact, first noted on this site in September, is why the remittitur was predictable: a plaintiff holding a large compensatory award with no punitive component has nothing to trade away when the trial judge concludes the number is too high.

Why did Judge Saris say the Covidien verdict was excessive?

Judge Saris called the award shocking, excessive and the product of passion. Each phrase maps onto a recognized legal test, and together they explain why the ruling took the form it did.

"Shocking" is the vocabulary of the federal excessiveness standard. In the First Circuit, which reviews District of Massachusetts judgments, a compensatory award is subject to remittitur when it is grossly excessive or so large that it shocks the conscience of the court. A trial judge who says an award shocks is saying, in effect, that it falls outside the range a reasonable jury could have reached on the evidence.

"Excessive" ties that conclusion to the record. Covidien's defense at trial and afterward was that Larry Patterson remained able to work and to carry out daily activities after his revision surgery, according to reporting on the closing arguments and post-trial briefing. The plaintiffs' case was that the Symbotex collagen barrier, represented to surgeons as lasting roughly thirty days, broke down in about a week, that Patterson suffered a bowel obstruction in 2020, and that the revision removed both the mesh and a section of intestine. A serious injury, but not a catastrophic or fatal one, is the type of record on which nine-figure compensatory awards for a single plaintiff are routinely reduced.

"Product of passion" is the most consequential phrase. It is the language courts use when they conclude that a jury was moved by emotion, sympathy or anger rather than by the evidence of loss. That finding is unusual for a verdict that, on the same day, declined to find fraud and declined to award Punitive Damages. The jury refused to punish Covidien but, in the judge's view, compensated the Pattersons as though it had.

There was also a forecast. At an August 19, 2026 status conference, Judge Saris told the parties she was likely to reduce the award, urged them toward settlement, and, according to USA Herald's report of the hearing, said she "would be surprised" if Covidien did not move for remittitur. She also noted that any new trial for the Pattersons would likely be more than a year away, a point she linked to Larry Patterson's health. The November 10 ruling is the formal follow-through on those remarks.

How much will the Covidien hernia mesh verdict be reduced to?

That number has not been reported. Neither the Law360 nor the Reuters account of the November 10 ruling gives a remitted figure, and any number circulating without a citation to a written order should be treated as speculation.

The law does say how the number is chosen. The general federal practice, followed in the First Circuit, is to remit to the maximum amount the evidence could support rather than to the amount the judge would personally have awarded. That rule protects the jury's role by leaving the plaintiff with the most generous award the record permits. In a diversity case such as Patterson, the substantive standard for excessiveness comes from state law under Gasperini v. Center for Humanities, Inc., 518 U.S. 415 (1996), while the federal court applies that standard through the procedure of Federal Rule of Civil Procedure 59.

Three practical anchors are therefore relevant, even though none fixes the result:

Anchor	What it tells the parties
Comparable reported compensatory awards for revision surgery with bowel resection	Courts benchmark against what juries and appellate courts have allowed for similar injuries under the governing state's law
Larry Patterson's economic losses as proved at trial	Medical expenses and earnings evidence set a floor; the defense's "still able to work" argument caps lost earning capacity
The consortium award ($11 million)	A spouse's award is usually measured against the injured spouse's; if the $77 million comes down, the $11 million is likely to be scrutinized in proportion

What the anchors rule out is the idea, common on intake and advertising pages, that the Pattersons' recovery will stay in the tens of millions as a matter of course. It may, or it may not. The point of the November 10 ruling is that the trial judge who heard every witness has concluded that $88 million is not a number the record can carry.

What is remittitur, and can the Pattersons refuse it?

Remittitur is a trial court's order offering a plaintiff a choice: accept a reduced award, or take a new trial on damages. The Pattersons can refuse it. If they do, the reduced figure falls away and a new jury decides damages.

That choice is constitutional, not discretionary. The Seventh Amendment's guarantee of a civil jury means a federal judge cannot simply substitute a lower number for the jury's verdict. The Supreme Court confirmed in Hetzel v. Prince William County, 523 U.S. 208 (1998), that a court which finds an award excessive must offer the plaintiff a new trial as the alternative to the reduction. The mirror-image rule, from Dimick v. Schiedt, 293 U.S. 474 (1935), is that a federal court cannot increase an inadequate award by additur; the option runs one way only.

The election has consequences that the Pattersons' counsel at Levin Papantonio will weigh carefully.

If they accept. The reduced award becomes the judgment, subject to Covidien's remaining challenges. Under Donovan v. Penn Shipping Co., 429 U.S. 648 (1977), a plaintiff who accepts a remittitur cannot then appeal to restore the original verdict. Acceptance trades the $88 million for certainty about the floor of the case and for speed.

If they refuse. The court orders a new trial, typically limited to damages if liability was fairly tried. Judge Saris has already estimated that a retrial would likely be more than a year away. A second jury could award more than the remitted figure, the same, or considerably less, and the entire liability record would remain exposed to Covidien's appeal in the meantime.

Timing pressure. The August hearing record shows that the court is aware of Larry Patterson's health. Delay has a human cost in personal injury litigation that it does not have in commercial disputes, and it is one reason plaintiffs in this posture usually accept.

What the Patterson jury heard about Symbotex

Understanding why the judge kept liability in place while cutting damages requires understanding what the case was about. Symbotex is a composite device: a polyester mesh on one side, and on the visceral side a resorbable collagen film intended to keep the mesh from adhering to the bowel and other organs while tissue grows into it. The barrier is designed to be temporary. The dispute was over how temporary.

The plaintiffs alleged that Covidien told implanting surgeons the collagen film would remain effective for roughly thirty days, and that internal information showed it largely dissolved within about a week. If that was right, the protection against adhesion disappeared before the healing window closed, and surgeons choosing Symbotex for an intraperitoneal repair were working from an inaccurate premise. Larry Patterson received Symbotex during a 2017 hernia repair, developed a bowel obstruction in 2020, and underwent a revision operation in which the mesh and a length of intestine were removed.

The jury accepted the warnings theory. Because the duty to warn about a prescription device runs to the physician, the question was whether surgeons were told enough, not whether Patterson read a label. That is a documentary question, answered with test data, instructions for use and sales training materials, and it is the kind of claim a plaintiff can win without proving intent to deceive. The jury's rejection of the fraud count shows it did exactly that.

Medtronic's position since the verdict has been consistent: it strongly disagrees with the result and said it would challenge both liability and the size of the award through post-trial motions and, if necessary, an appeal. The November 10 ruling gives it the second of those objectives in part. The first remains pending.

Remittitur or a full new trial: why "product of passion" matters

Most reporting has treated the ruling as a straightforward trim. The phrase "product of passion" complicates that.

Federal courts distinguish between two kinds of excessive verdict. In the first, the jury simply overvalued the injury, perhaps because the evidence of pain was vivid or the plaintiff's counsel anchored on a large number. Remittitur is the ordinary cure. In the second, the excessive amount is evidence that passion or prejudice infected the jury's deliberations as a whole. Where that is shown, many courts hold that the taint may reach the liability finding as well, so that a new trial on all issues, rather than a reduction, is the appropriate remedy.

Covidien has every incentive to argue that the second category applies. Its September 4, 2026 post-trial motions sought judgment as a matter of law, a new trial, and amendment of the judgment. If the court has found that passion drove the damages, Covidien can contend that the same jury's Failure to Warn finding cannot be trusted either, particularly where the theory turned on a contested reading of internal testing and instructions for use under the Learned Intermediary Doctrine.

The plaintiffs have a strong answer: the jury's own verdict form. A jury overtaken by passion does not usually reject the fraud claim and decline to award punitive damages. The split verdict is the best evidence that these jurors discriminated between theories and followed instructions on liability, even if their damages figure overshot. Judge Saris's decision to announce a reduction, rather than a new trial on everything, suggests she reads the record the same way. Until the written order is entered, that remains an inference from the form of the ruling, not a reported holding.

The post-trial timeline in Patterson v. Covidien

Date	Event
July 13, 2026	First federal Covidien bellwether trial opens in Boston
Aug. 4, 2026	Jury returns $88 million: $77 million to Larry Patterson, $11 million to Tammy Patterson; failure to warn found; fraud and punitive damages rejected
Aug. 19, 2026	Status conference: Judge Saris says she is likely to reduce the award and urges settlement
Sept. 4, 2026	Covidien files motions for judgment as a matter of law, new trial, and to alter or amend the judgment
Week of Sept. 15, 2026	Scheduling order reported setting the second bellwether for Jan. 11, 2027
Nov. 10, 2026	Judge Saris says she will reduce the verdict, calling it shocking, excessive and the product of passion
Pending	Written remittitur order fixing the amount; the Pattersons' election; rulings on the remaining post-trial motions
Then	Final judgment; 30-day window for notice of appeal to the First Circuit

The appellate clock is easy to misread. Under Federal Rule of Appellate Procedure 4(a)(4), a timely motion for judgment as a matter of law or for a new trial suspends the time to appeal until the district court disposes of the last such motion. Covidien's 30 days to notice an appeal therefore will not begin until Judge Saris rules on all of its September 4 motions and judgment is entered on whatever award survives. If the Pattersons reject the remittitur and a damages retrial is ordered, there is no appealable final judgment until that retrial ends.

What happens next in the Covidien hernia mesh MDL?

Three things happen next: a written order, the Pattersons' election, and the second bellwether trial on January 11, 2027.

The written order. Judge Saris's statement of intent must be reduced to an order that fixes the remitted amount, explains the basis for it, and disposes of Covidien's motion for judgment as a matter of law. That last part is as important to the MDL as the dollar figure. A denial of judgment as a matter of law would confirm that the plaintiffs' warning theory survived post-trial scrutiny, which is what gives the bellwether its value to the rest of the inventory.

The election. Once the figure is set, the Pattersons will have a period fixed by the court to accept or reject it. The choice will be watched less for its effect on one Alabama family than for what it tells both sides about how plaintiffs' leadership values Symbotex cases.

The Stephen trial. The second bellwether, brought by Mississippi plaintiff Regina Stephen over a Symbotex patch implanted during a 2017 ventral hernia repair, is set for January 11, 2027, with motions in limine reportedly due November 13 and a final pretrial conference on December 10, 2026. Nothing in the November 10 ruling moves that date. The court has consistently kept the bellwether calendar running independently of the post-trial fight in Patterson.

When is the next Covidien hernia mesh bellwether trial?

The next Covidien hernia mesh bellwether trial is Stephen, set to begin January 11, 2027 before Judge Saris in the District of Massachusetts. Like Patterson, it is a Symbotex case, which means the jury will hear much the same evidence about the collagen barrier's duration and the adequacy of Covidien's warnings to surgeons.

The remittitur changes the stakes of that trial in two ways. First, it lowers the reference point. A Stephen jury will not be told about Patterson, but every lawyer in the case will be measuring a January verdict against a remitted number rather than against $88 million. Second, it signals the ceiling Judge Saris will tolerate. A comparable damages award in Stephen would almost certainly draw a comparable remittitur motion, and both sides now know how the court is likely to rule on one.

Bellwether trials exist to generate information both sides can price. Before November 10, the docket had one data point and it was an outlier. After November 10, it has one data point that the trial judge has publicly classified as an outlier. That is useful information for a settlement negotiation, and it is the main reason this ruling matters beyond the Patterson family.

Does the reduction affect other Covidien hernia mesh lawsuits and settlement values?

Not directly, but it changes the negotiation. A bellwether verdict binds only the parties to it, so the remittitur does not reduce any other plaintiff's claim. Its effect is on valuation: it takes the most aggressive number in the litigation off the table and replaces it with a court-sanctioned maximum that will be lower.

The size of the docket explains why that matters. MDL No. 3029 held 2,453 pending actions on the Judicial Panel on Multidistrict Litigation's September 1, 2026 report, and Medtronic's disclosures describe roughly 7,450 additional plaintiffs in Massachusetts state court and about 10,350 nationally across forums. The federal Multidistrict Litigation (MDL) is the smaller part of the exposure, but it is the part generating trial results.

Valuation input	Before Nov. 10	After Nov. 10
Highest tried result	$88 million (jury)	Remitted amount, not yet fixed
Trial judge's view of that result	Unknown beyond "likely" reduction	Shocking, excessive, product of passion
Punitive exposure shown at trial	None	None
Liability theory tested	Failure to warn, Symbotex	Unchanged, subject to pending JMOL ruling
Second data point	Jan. 11, 2027	Jan. 11, 2027

For claimants, the honest reading is that the November 10 ruling was always the likely outcome and does not by itself weaken the merits. The jury found that surgeons were not adequately warned, and that finding is what drives the inventory. What has narrowed is the argument that a Symbotex revision case is worth eight or nine figures at trial.

For Medtronic, the ruling is a partial win that falls short of what it asked for. A remittitur that leaves liability intact preserves the plaintiffs' core theory for Stephen and for every state-court case built on the same documents.

Is there a Covidien hernia mesh settlement?

No. There is no Covidien hernia mesh settlement, no announced Global Settlement, no Settlement Matrix and no Qualified Settlement Fund (QSF). Mediation sessions in late March 2026 produced no agreement, and nothing has been announced since the Patterson verdict, despite Judge Saris's August encouragement to settle.

The comparison every claimant reaches for is Becton Dickinson's resolution of the Bard and Davol hernia mesh litigation, announced on October 2, 2024, which exceeded $1 billion across more than 38,000 claims. That implies a gross average in the mid-five figures per claim before fees, costs and liens. Covidien's docket is far smaller, and its one trial went for the plaintiffs, so its per-claim economics need not track Bard's. But the November 10 ruling moves the conversation away from the $88 million headline and back toward the kind of structured, injury-tiered framework that resolved Bard.

A court's public statement that a bellwether award reflects passion is also, in practice, an invitation to both sides. Judge Saris pressed for settlement in August. A remittitur order that lowers the ceiling while preserving liability is the sort of ruling that often precedes serious resolution talks in a mature Mass Tort docket.

What it means for claimants' counsel, defendants and the PI bar

For plaintiffs' leadership and firms holding Covidien inventory. The verdict's liability finding, not its dollar figure, is the asset. Intake and client communications that quoted $88 million as a measure of case value should be revisited; a court has now said that figure is excessive. Firms should watch the written order for two things: the remitted amount, which becomes the practical ceiling for Symbotex revision cases before this court, and the ruling on judgment as a matter of law, which determines whether the warning theory is secure going into Stephen.

For Medtronic and device defendants generally. The ruling confirms the value of building a record on functional recovery. The defense theme that Larry Patterson kept working and living independently is the type of evidence that does little to win a liability verdict but a great deal to win a remittitur. Defendants in other bellwether programs, including those tracked on this site in device and pharmaceutical dockets, will note that a split verdict with no fraud and no punitive damages remains vulnerable on compensatory size alone.

For trial lawyers in single-plaintiff device cases. Damages presentations that invite a jury to punish through the compensatory line carry a known cost. Judges reviewing compensatory awards look for proportion between the proved injury and the number. An award that the jury itself declined to label punitive will still be cut if it functions as one.

For funders and lien holders. A remitted bellwether shortens the tail on expected recoveries. Litigation funders underwriting hernia mesh portfolios, and Medicare and private plans asserting a Medical Lien against eventual settlements, should treat the remitted number, not the jury's, as the trial benchmark.

For claimants. Nothing about the ruling changes eligibility to bring or continue a claim. It changes expectations. A claim's value will turn on the same facts it always did: the product, the injury, whether revision surgery was required, and the strength of the medical record.

How this ruling compares with other recent verdict reductions

Large compensatory verdicts are routinely cut after trial, and the Covidien hernia mesh verdict reduced on November 10 follows a familiar pattern. Trial judges are most willing to remit where three conditions coincide: the injury, though serious, is not fatal or permanently disabling; the award greatly exceeds the proved economic loss; and the non-economic component carries most of the weight. Patterson fits all three.

What distinguishes this ruling is the setting. In a bellwether program, a remittitur is not just a correction for one family; it is a court-issued valuation signal for thousands of related claims. That is why bellwether judges are often more cautious about leaving an outlier award in place than they would be in a stand-alone case. A verdict that the court considers aberrational distorts the information the bellwether process is designed to produce, and the Bellwether Trial mechanism only works if its results can be priced.

Frequently asked questions

Did the judge reduce the $88 million Covidien hernia mesh verdict?

Judge Patti B. Saris said on November 10, 2026 that she will reduce the $88 million Patterson v. Covidien verdict, calling it shocking, excessive and the product of passion. A written order fixing the reduced amount had not been reported as of that date.

Why was the Covidien verdict considered excessive?

The judge found the award shocking and the product of passion. The defense argued that Larry Patterson remained able to work and carry out daily activities after revision surgery, and the entire $88 million was compensatory, with no punitive damages to absorb any reduction.

Can the Pattersons reject the reduction?

Yes. Under Hetzel v. Prince William County (1998), a federal court that finds an award excessive must offer the plaintiff a new trial on damages as the alternative. If the Pattersons accept, Donovan v. Penn Shipping (1977) bars them from appealing to restore the full award.

When is the next Covidien hernia mesh trial?

The second bellwether, Stephen, a Symbotex case brought by a Mississippi plaintiff, is set for January 11, 2027 in the District of Massachusetts, with a final pretrial conference reported for December 10, 2026.

Is there a Covidien hernia mesh settlement?

No. As of November 10, 2026 there is no Covidien hernia mesh settlement, fund or matrix. Mediation in March 2026 failed, and 2,453 cases were pending in MDL No. 3029 on September 1, 2026.

Does the ruling reduce other Covidien hernia mesh claims?

No. A bellwether verdict binds only its parties. The ruling affects other claims indirectly, by lowering the top trial benchmark that both sides use to value the inventory.